Healthcare Costs and Workloss Burden of Patients with Chemotherapy-Associated Peripheral Neuropathy in Breast, Ovarian, Head and Neck, and Nonsmall Cell Lung Cancer
Table 1
Inclusion criteria and ICD-9-CM codes used for analytic samples.
(a) Inclusion criteria
Criteria
Number of patients
1
Number of beneficiaries under 65 at eligibility start
4,729,443
2
>1 breast, ovarian, head and neck, or nonsmall cell lung cancer claim from 1999–2005
56,261
3
>1 chemotherapy treatment within 3 months following a breast, ovarian, head and neck, or nonsmall cell lung cancer diagnosis
14,142
4
>3 months of continuous eligibility prior to the first chemotherapy treatment for the qualifying tumor during which no other chemotherapy treatment was received
11,009
5
>1 diagnosis for peripheral neuropathy following first chemotherapy treatment
1,245
6
Peripheral neuropathy within 9 months of first chemotherapy treatment
525
Main CAPN sample: no diabetes history
454
Diabetic CAPN sample
71
Employee CAPN subsample
78
(b) ICD-9-CM Diagnosis Codes Used for Identification of CAPN and Cancer
